Not a head-to-head peptide comparison — the single most important distinction in this whole space, explained plainly.
Almost every peptide question that trips people up comes down to confusing three different things. Here they are, cleanly separated.1
FDA-approved — a specific manufacturer’s product went through the FDA’s review of safety, efficacy, and manufacturing quality and can be marketed for defined uses. Semaglutide (Wegovy) and tirzepatide (Zepbound) are examples.
Compounded (503A/503B) — a licensed pharmacy prepares a medication for a patient’s specific need. It is not FDA-approved and not individually reviewed for safety and efficacy, though the pharmacies themselves are licensed and inspected.2
Gray-market “research only” — vials sold online with disclaimers, outside the pharmacy system entirely. This is the riskiest category — no clinical oversight, unverified purity.
| FDA-approved | Compounded (503A/503B) | |
|---|---|---|
| FDA review | Yes — safety, efficacy, manufacturing | No — not individually reviewed2 |
| Who makes it | The approved manufacturer | A licensed compounding pharmacy |
| Oversight | FDA-regulated product + provider | State/FDA-licensed pharmacy + provider |
| Consistency | Standardized, batch-controlled | Varies by pharmacy; ask about testing |
| Typical examples | Wegovy, Zepbound, Egrifta | Compounded semaglutide; many peptides where permitted |
| Requires a provider | Yes | Yes |
Gray-market “research only” vials are a separate, unregulated category and are not represented here as a legitimate option.
The confusion peaks around the FDA’s Category 2 list (“do not compound”). In 2023 the FDA moved roughly 19 peptides to Category 2; in April 2026 it removed 12 of them. Marketing quickly translated “off Category 2” into “now legal and safe” — which isn’t what it means.3
Three gates, not one. A peptide can clear the first and still be nowhere near the third.
Compounded does not automatically mean unsafe. Legitimate 503A and 503B pharmacies are licensed, inspected, and — the good ones — third-party test for potency, sterility, and endotoxins. Compounding exists for real clinical reasons.2
But because compounded products aren’t individually FDA-reviewed, quality varies, and the FDA has specifically warned about unapproved GLP-1 products. The gray market — “research only” vials — is a different animal entirely: no clinical oversight, unverified contents, and real safety risk. The safeguard is the same throughout: a licensed provider and an accredited pharmacy.
This is education, not legal or medical advice. Regulation moves fast and varies by product and state. A licensed provider and pharmacy determine what’s appropriate and lawful for you. Statements have not been evaluated by the FDA.
In April 2026 the FDA removed 12 peptides from Category 2. A PCAC review on July 23–24, 2026 is weighing several more (including BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon), with another docket around February 2027.3 The committee recommends; formal rulemaking follows and can take a year or more.
So the ground is genuinely shifting — which is exactly why “off Category 2 ≠ 503A-compoundable ≠ FDA-approved” is the sentence to remember. See our peptide legality explainer for the fuller timeline.
Citations are flagged for the site-wide citation pass — this is a YMYL/legal page, so accuracy of dates and framework language matters most. Don’t invent specifics.
Whether any option is appropriate or legitimate for you is a question for a licensed provider.
An FDA-approved drug has passed the FDA’s review of safety, efficacy, and manufacturing. A compounded product is made by a pharmacy for a specific need and is not FDA-approved or individually reviewed for safety and efficacy — a different regulatory category.
No. Wegovy is the FDA-approved branded product; compounded semaglutide is not FDA-approved and is regulated differently. The FDA has warned about unapproved GLP-1 drugs.
Not necessarily. Off Category 2, 503A-compoundable, and FDA-approved are three separate things. Coming off the do-not-compound list is a status change, not automatic clearance to compound or a drug approval.
Not automatically — legitimate 503A/503B pharmacies are licensed and inspected. But compounded products aren’t individually FDA-reviewed, and quality varies, which is why a licensed provider and accredited pharmacy matter.